BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Abbott Laboratories (ABT) Results Bode Well for Spun-Off AbbVie (ABBV)


1/24/2013 7:03:51 AM

AbbVie Inc (ABBV.N), the new branded pharmaceuticals company spun off by Abbott Laboratories Inc (ABT.N), is off to a good start, judging by fourth-quarter sales of arthritis drug Humira and other products in its medicine chest. The picture, although healthy, could be more challenging for the remaining Abbott, nicknamed "new Abbott," which continues to sell medical devices, diagnostics, nutritional products and generic drugs, said analysts. The new Abbott said it expects earnings for 2013, excluding special items, of $1.98 to $2.04 per share, in line with its earlier guidance and above the average Wall Street forecast of $1.95. Although the company has not yet provided complete earnings data for full-year 2012, it said the mid-point of its 2013 profit forecast would likely represent double-digit earnings growth. But Abbott is still analyzing its numbers because of the split and may eventually restate some figures, analysts said. A big worry, according to Leerink Swann analyst Danielle Antalffy, is whether Abbott can revive sales of its branded generic medicines, which the company calls established pharmaceuticals. Sales of the products slipped 4 percent in 2012 to $5.1 billion. Abbott predicted they would capture mid-single-digit growth this year, excluding the impact of foreign exchange rates. "The business, which represents 25 percent of company sales, has been underperforming," Antalffy said, adding that revenue forecasts for the business are difficult because they rely on data from so many local markets and countries.

Read at Reuters
Read at Irish Times
Read at MorningStar.com

Abbott
AbbVie
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->